Abstract: Monoamine oxidase A (MAOA) is an important mitochondria-bound enzyme that catalyzes the oxidative deamination of monoamine neurotransmitters. Accumulating evidence suggests a significant association of increased MAOA expression and advanced high-grade prostate cancer (PCa) progression and metastasis. Herein, a series of novel conjugates combining the MAOA inhibitor isoniazid (INH) and tumor-targeting near-infrared (NIR) heptamethine cyanine dyes were designed and synthesized. The synthesized compounds G1-G13 were evaluated in vitro for their cytotoxicity against PC-3 cells using the MTT assay, and molecular docking studies were performed. Results showed that most tested compounds exhibited improved antitumor efficacy compared with INH. Moreover, conjugates G10 and G11 showed potent anticancer activity with IC 50 values (0.85 and 0.4 µM respectively) comparable to that of doxorubicin (DOX). This may be attributable to the preferential accumulation of these conjugates in tumor cells. G10, G11, and G12 also demonstrated moderate MAOA inhibitory activities. This result and the results of molecular docking studies were consistent with their cytotoxicity activities. Taken together, these data suggest that a combination of the MAOA inhibitor INH with tumor-targeting heptamethine cyanine dyes may prove to be a highly promising tool for the treatment of advanced prostate cancer.
Introduction
Global prostate cancer (PCa) incidence and mortality have substantially increased, compounded by an increase in the proportion of the elderly population and in the frequency of diagnosis. Although the majority of cases with metastatic PCa respond to the available therapeutic modalities, hormone-refractory PCa and advanced metastatic PCa remain inevitable [1] [2] [3] [4] . Therefore, novel and highly effective treatments with high tumor-targeting specificity, fewer side effects, and improved efficacy are desirable for hormone-refractory PCa and metastatic PCa. 
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Cytotoxicity against PC-3
The antitumor activities of G1-G13 were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using a human PC-3 cell line. The IC50 values of G1-G13 against PC-3 cells are summarized in Table 1 . 
The antitumor activities of G1-G13 were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using a human PC-3 cell line. The IC 50 values of G1-G13 against PC-3 cells are summarized in Table 1 . 
MTT assay results revealed that nearly all tested compounds showed improved antitumor activity when compared with their parent compound, the MAOA inhibitor INH. The moderate cytotoxicity of these conjugates may be due to their preferential uptake by PC-3 cells mediated by OATPs and subsequent accumulation in the mitochondria of PC-3 cells, disrupting mitochondrial activities. The fact that INH exhibited negligible cytotoxicity may be attributed to its poor passive diffusion into PC-3 cells. G10, G11 (IC 50 values of 0.85 and 0.40 µM, respectively) possessed potent cytotoxicity comparable to that of doxorubicin (DOX) (IC 50 = 0.21 µM). G10 and G11 have very similar chemical structures except for the different chain length of carboxyalkyl connected to the N atom in indole moieties. Their structural similarity may explain their similar antitumor efficacy. These results indicated that the conjugation with INH was conducive to the enhancement of anti-tumor activity against PC-3 in vitro.
MAOA Inhibitory Activity of G10, G11, and G12
Because the prostate cancer cell line LNCaP expressed a relatively high level of MAOA [17, 40] , we tested the inhibitory effect of compounds G10, G11, and G12 on MAOA using LNCaP cells (Table 2) . Our data showed that three synthesized novel compounds displayed an enhanced inhibitory action on MAOA levels as compared with the parent compound INH, while clorgyline-another MAOA inhibitor-exhibited the most potent inhibitory effect. The fact that heptamethine dye-INH conjugates possessed higher MAOA inhibition efficacy than INH may be attributed to the modification of the terminal hydrazine group in INH. This assay result is consistent with that of the cell viability assay, suggesting that the tested compounds inhibited cell growth by suppressing MAOA activity. 
In Silico Molecular Docking
To clarify the underlying mechanism of action of these compounds at the molecular level, molecular docking of 2BXR and G11 was performed. 2BXR is a human monoamine oxidase A (hMAOA). De Colibus et al. revealed that the active binding site of hMAOA was formed primarily by a single cavity consisting of residues 210-216 (all active site residues: Tyr69, Gln74, Val91, Val93, Leu97, Ile207, Phe208, Ser209, Val210, Glu216, Cys323, Ile325, Ile335, Leu337, Met350, Phe352, Tyr407, Tyr444) [41] . Since G11 showed the best in vitro antitumor activity, it was selected as the ligand for this docking analysis. The molecular docking analysis showed the heptamethine chain and indole moieties of G11 could be integrated closely with the hydrophobic active site cavity (Figure 2 ) with the low binding energy of (∆G) −12.27 kcal/mol. The docked pose of G11 (in 2BXR) was enclosed by a partially hydrophobic cavity with amino acid residues including Tyr69, Val93, Leu97, Ile180, Ile207, Phe208, Phe208, Val210, Cys323, Ile325, Ile335, Leu337, Met350, Phe352, Tyr407, and Tyr444. A hydrogen bond interaction between O44 and Ser209 was also observed. 
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Materials
All reagents and solvents were obtained from commercial sources and were used as received unless otherwise stated. Phenylhydrazine hydrochloride, 4-bromophenylhydrazine hydrochloride, 4-methylphenylhydrazine hydrochloride, 4-methoxyphenylhydrazine hydrochloride, 6-bromohexanoic acid, ethyl 4-bromobutyrate, and 1-bromobutane were purchased from Meryer (Shanghai, China). 3-Methyl-2-butanone, 3-methyl-2-pentanone, 1,4-butane sultone, and isoniazid were purchased from Aladdin (Shanghai, China). Clorgyline was obtained from Bide Pharmatech Ltd. (Shanghai, China). All other reagents were synthesized in our laboratory. 1640 DMEM and 0.25% trypsin EDTA were obtained from Gibco (Sigma-Aldrich, St. Louis, MO, USA). (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). MTT reagent was acquired from Sigma-Aldrich (St. Louis, MO, USA). PC-3 and LNCaP cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China).
Molecular Docking
The crystal structure of MAOA with a resolution of 3 Å was retrieved from the Protein Data Bank (PDBID: 2BXR). AutoDock 4.2 suite, an automated docking tool that uses a Lamarckian genetic algorithm (LGA), was used to perform the molecular docking simulations [42] . Briefly, all the bound water molecules, ligands, and co-factors were eliminated from the protein, and the polar hydrogen was added to the proteins. Gasteiger charges were computed in AutoDockTools 4.2 [43] . 2D structures of G11 were constructed using ChemBioDraw ultra12.0 and were transformed to 3D. Subsequently, 3D structures of the aforementioned compounds were also deduced and then the structure was energetically minimized by using an MMFF94 force field.
In the docking process the grid point maps were calculated using AutoGrid 4.2. The program AutoGrid was used to generate the grid maps. Each grid was centered at the structure of the corresponding receptor. The grid dimensions for the grid maps were fixed at a spacing of 0.375 Å with the grid box of size 90 × 70 × 60 (number of points in x-, y-, and z-axes for both proteins). For each docking experiment, default parameters for docking run included number of final conformations, 100; population size, 150; maximum number of energy evaluations, 2.5 × 10 6 , and maximum number of generations, 27,000. Some low-binding-energy docked poses were investigated in detail for their binding interactions with the binding cavity of the target protein, using Discovery Studio Visualizer (DSV). The docked compound complexes were built using the low-free-energy binding positions.
Cytotoxicity Evaluation
The in vitro cytotoxicity activity of G1-G13 were measured by the colorimetric MTT assay. Briefly, PC-3 cells were incubated in 96-well plates at a density of 3 × 10 3 cells/well for 24 h. Then, the cells were exposed to various concentrations of tested compounds, INH and DOX, respectively for 96 h. After incubation, 10 µL of MTT (5 mg/mL) solution was added and the plates were incubated for 4 h at 37 • C. Next, the medium was replaced with 200 µL of DMSO to dissolve the formed formazan crystals. The absorbance was measured at 570 nm on a microplate reader (Synergy-HT, BioTek Instruments, Winooski, VT, USA).
MAOA Inhibition Activity Assay
In a 10-mm dish, 6 × 10 5 LNCaP cells were plated in medium supplemented with 10% FBS. After 24 h, cells were treated with various concentrations (10 pM, 1 nM, 100 nM, 10 µM) of the tested compounds G10, G11, G12, isoniazid, and clorgyline for 48 h. The reaction products were extracted and MAOA activities were measured as described in the introduction for the Cell MAOA Assay Kit (Shanghai Chengong Biotechnology, CHN, Lot No: 1-201838-10). The MAOA activity was assessed based on the substrate p-tyramine level after treatment with MAOB inhibitor pargyline.
General Procedure for the Synthesis of Compounds G1-G3
(E)-2-Chloro-3-(hydroxymethylene)-cyclohex-1-enecarbaldehyde (3) (500 mg, 2.9 mmol), 5-methoxyl-1-(5-carboxypentyl)-2,3,3-trimethyl-3H-indol-1-ium bromide (1a) (2.23 g, 5.8 mmol) and sodium acetate (401 mg, 2.9 mmol) were suspended in acetic anhydride, the mixture was stirred at 60 • C for 1 h. Next the resulting solution was poured into water. Precipitation was allowed to proceed for 6 h and then mixture was filtered to obtain intermediate 4a as a gold solid. DCC (104 mg, 0.506 mmol) and DMAP (6 mg, 0.051 mmol) were added to a solution of 4a (400 mg, 0.506 mmol) in DCM in an ice-salt bath. INH (58 mg, 0.422 mmol) was added dropwise, the mixture was stirred for 24 h, and was then filtered. Filtrate was evaporated to dryness under reduced pressure and the residue was purified by silica gel column to yield G1 (50 mg, 13%). G2 and G3 were prepared by the same procedure as G1 (Supplementary Materials). 
2-(2-(3-(2-(
5-Methoxyl-1-(5-carboxypentyl)-3,3-dimethyl-indol-2-ylidene)ethylidene)-2-chloro-1-cyclohexen-1- yl)vinyl)-5-methoxyl-1-(6-(2-isonicotinoylhydrazinyl)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium bromide (G1
5-Bromo-1-(5-carboxypentyl)-3,3-dimethyl-indol-2-ylidene)ethylidene)-2-chloro-1-cyclohexen-1- yl)vinyl)-5-bromo-1-(6-(2-isonicotinoylhydrazinyl)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium bromide (G2
5-Methoxyl-1-(5-carboxypentyl)-5-ethyl-3-methyl-indol-2-ylidene)ethylidene)-2-chloro-1-cyclohexen-1- yl)vinyl)-5-methoxyl-1-(6-(2-isonicotinoylhydrazinyl)-6-oxohexyl)-5-ethyl-3-methyl-3H-indol-1-ium bromide (G3
General Procedure for the Synthesis of Compounds G4-G6
1-Phenylamino-5-phenylimino-1,3-pentadiene hydrochloride (5) (500 mg, 1.76 mmol), 1-(5-carboxypentyl)-2,3,3,5-tetramethyl-3H-indol-1-ium bromide (1a) (1.30 g, 3.52 mmol), and triethylamine (1 mL) were dissolved in acetic anhydride, and the mixture was stirred at 60 • C for 1 h. Afterwards, the resulting solution was added to water and allowed to stand for 1 h followed by extraction with ethyl acetate. The organic layer was dried over Mg 2 SO 4 and concentrated. The residue was purified by chromatography on silica gel to get 6a. Next, DCC (86 mg, 0.419 mmol) and DMAP (5 mg, 0.04 mmol) were added to a solution of 6a (300 mg, 0.419 mmol) in DCM in an ice-salt bath. After cooling to room temperature, INH (52 mg, 0.377 mmol) was added, and the mixture was stirred for 24 h. After filtration, the filtrate was evaporated in vacuo and the residue was purified by silica gel column to yield G4 (60 mg, 17%). G5 and G6 were prepared by the same procedure as G4.
2- (7-(1-(5-carboxypentyl)-1,3-dihydro-3,3,5-trimethyl-2H-indol-2-ylidene)-1,3,5-heptatrien-1-yl)-1-(6-(2-isonicotinoylhydrazinyl)-6-oxohexyl) 28 (s, 2H), 7.20 (d, 1H), 7.18 (d, 1H), 7.14 (t, 2H), 6.51 (t, 1H), 6.43 (t, 1H), 6.25 (d, 1H), 6.19 (d, 1H) 
General Procedure for the Synthesis of Compounds G7-G13
1-Phenylamino-5-phenylimino-1,3-pentadiene hydrochloride (5) (500 mg, 1.76 mmol) and 4-(5-methoxy-2,3,3-trimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate (2a) were added to acetic anhydride with continuous stirring at 50 • C for 1 h. The mixture was poured into diethyl ether after cooling to room temperature. Then, precipitate (A) was filtered and used in further reaction without any purification.
1-(5-Carboxypentyl)-2,3,3,5-tetramethyl-3H-indol-1-ium bromide (1a) (352 mg, 0.956 mmol) was added to a solution of A (500 mg, 0.956 mmol) in 25 mL pyridine. The resulting solution was stirred at 60 • C for 30 min. Diethyl ether was added in excess to the mixture to obtain the precipitate after cooling to room temperature. The resulting mixture was acidified with hydrochloric acid to get 6d. Subsequently, DCC (92 mg, 0.445 mmol) and DMAP (5 mg, 0.04 mmol) were added to a solution of 6d (300 mg, 0.445 mmol) in DCM in an ice-salt bath. After the mixture was cooled to room temperature, INH (76 mg, 0.557 mmol) was added slowly. 
Conclusions
In this study, we developed a series of novel near-infrared heptamethine dye-INH conjugates. Evaluation of IC 50 values indicated that nearly all conjugates showed moderate antitumor efficacy. Among them, conjugates G10 and G11 exhibited strong cytotoxicity comparable to doxorubicin in inhibiting PC-3 cell growth while INH showed negligible in vitro antitumor activity. Furthermore, MAOA inhibitory activities of G10, G11, and G12 and molecular docking analysis were consistent with the cell viability results, suggesting that the enhanced antitumor activity of these conjugates may be attributed to the preferential accumulation in cancer cells mediated by OATPs and the increased MAOA inhibitory activity derived from INH N-acylation. All these above results suggested that a combination of the MAOA inhibitor INH and tumor-specific targeting heptamethine cyanine dyes may provide a promising tool for the treatment of advanced prostate cancer.
